

Table S1 Clinical timeline and renal function parameters of the patient

Time point	Clinical event	Scr ($\mu\text{mol/L}$)	eGFR (mL/min)
Baseline	Before immunotherapy	73.3	128
Onset of AKI	After 5 cycles of envafolimab	106	82
Peak AKI	October 2023	163	49
Last follow-up	March 2024	104.8	82




Figure S1 Scr time variation chart (March 2023 to February 2024). This figure shows dynamic trends of serum creatinine (Scr; normal: 57-97 $\mu\text{mol/L}$) levels during treatment.




Figure S2 eGFR time variation chart (March 2023 to February 2024). This figure shows the temporal trend of eGFR (normal >90 mL/min) during treatment. The y-axis shows eGFR values, the x-axis marks timeline, with quantified dynamics visually illustrating treatment phase impacts on renal function.